Eli Lilly & CompanyLLY announced that the FDA has approved the inclusion of additional data on the label of its psoriasis injection, Taltz. With the latest approval, Taltz label will now include data ...
The SPIRIT-H2H trial is the first completed large head-to-head or H2H superiority study in active PsA. This open-label, randomized, controlled trial is the first and only H2H study that utilizes ...
Eli Lilly and Co., boosted by strong sales of diabetes drug Trulicity and psoriasis therapy Taltz, reported a fourth-quarter profit of $1.5 billion on Thursday, topping market expectations. The ...
Eli Lilly and Company LLY announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson’s Stelara (ustekinumab) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback